Financial Architects (New Jersey)’s Oramed Pharmaceuticals ORMP Stock Holding History

Financial Architects (New Jersey)’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,750	Closed	-$18K	–	1454
2018 Q1	$18K	Hold	2,750	–	–	﹤0.01%	910
2017 Q4	$25K	Hold	2,750	–	–	﹤0.01%	912
2017 Q3	$27K	Buy	2,750 +750	+38%	+$6.47K	﹤0.01%	888
2017 Q2	$16K	Hold	2,000	–	–	﹤0.01%	1023
2017 Q1	$12K	Hold	2,000	–	–	﹤0.01%	1090
2016 Q4	$12K	Hold	2,000	–	–	﹤0.01%	967
2016 Q3	$15K	Sell	2,000 -1,450	-42%	-$11.3K	﹤0.01%	912
2016 Q2	$29K	Buy	+3,450	New	+$29.4K	0.01%	680

Other funds holding ORMP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

RPC

Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Financial Architects (New Jersey)'s ORMP Position: Q2 2018 in Review

Financial Architects (New Jersey) sold out of Oramed Pharmaceuticals (ORMP) in Q2 2018, closing a stake of 2,750 shares — an estimated $18K sold.

Financial Architects (New Jersey) first reported a position in ORMP in Q2 2016 and held it in 8 quarters. The position peaked at $29K in Q2 2016. 21 funds tracked by Wall St. Rank hold ORMP as of Q2 2018.

Financial Architects (New Jersey) reported no remaining Oramed Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Financial Architects (New Jersey) sold 2,750 Oramed Pharmaceuticals shares in Q2 2018, an estimated $18K.
Financial Architects (New Jersey) first reported a position in Oramed Pharmaceuticals in Q2 2016 and held it in 8 quarters.
Financial Architects (New Jersey)'s Oramed Pharmaceuticals position peaked at $29K in Q2 2016.
21 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2018, filed 3 Aug 2018.